Rho-Kinase Inhibitors for the Treatment of Refractory Diabetic Macular Oedema.

ABSTRACT: Diabetic macular oedema (DMO) is one of the leading causes of vision loss associated with diabetic retinopathy (DR). New insights in managing this condition have changed the paradigm in its treatment, with intravitreal injections of antivascular endothelial growth factor (anti-VEGF) having become the standard therapy for DMO worldwide. However, there is no single standard therapy for all patients DMO refractory to anti-VEGF treatment; thus, further investigation is still needed. The key obstacles in developing suitable therapeutics for refractory DMO lie in its complex pathophysiology; therefore, there is an opportunity for further improvements in the progress and applications of new drugs. Previous studies have indicated that Rho-associated kinase (Rho-kinase/ROCK) is an essential molecul

SUBMITTER: Mateos-Olivares M 

PROVIDER: S-EPMC8307715 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature